Help us: Donate
Follow us on:
×

Kelsey Moody — Antibody Mimetic for Parkinson’s Disease

Share

Today, we would like to share with you the talk given by Kelsey Moody, CEO of Biotech Company Ichor, at the recent Ending Age-Related Diseases: Investment Prospects & Advances in Research conference in New York City. In this talk, Kelsey discusses Ichor’s protein engineering platform, how Ichor has used it, and Ichor’s plans for using it to discover new classes of drugs for age-related diseases.

Kelsey is a process-oriented biotechnology executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, he has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated contract research organization that focuses on preclinical research services for aging pathways. Proceeds from this work are used to self-fund R&D initiatives that constitute Ichor’s portfolio companies in enzyme therapy (Lysoclear, Inc.), small molecule drug discovery (Antoxerene, Inc.), and protein engineering (RecombiPure, Inc.) Kelsey has received graduate-level training in medicine, business, and laboratory research.

Kelsey is very much a rising star in the field, and we suspect that he may become one of the most important people in the development of therapies in the next few years, judging by his impressive track record to date. We are watching the work that Ichor and its portfolio companies are doing with great interest, and we are grateful to Kelsey for giving this talk, for sponsoring the conference, and for continuing to be a driving force for progress against age-related diseases.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
  1. August 21, 2018

    I think a huge market could be a topical RPTag to il4r which is targeted by Sanofi’s Durpexent antibody for eczema.

Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.